The Conversation (0)
October 14, 2024
Invion Limited's (ASX: IVX) (“Invion” or the “Company”) notification of security consolidation or split.
ANNOUNCEMENT SUMMARY
Applicable security for the reorganisation
IVX ORDINARY FULLY PAID
IVXAX OPTION EXPIRING 22-OCT-2024 EX $0.0177
IVXAZ OPTION EXPIRING 31-OCT-2024 EX $0.0106
IVXAAK OPTION EXPIRING 01-MAY-2026 EX $0.01
IVXAAJ OPTION EXPIRING 13-JAN-2026 EX NIL
IVXAAC OPTION EXPIRING 23-SEP-2025 EX $0.017
IVXAAI OPTION EXPIRING 17-NOV-2026 EX NIL
IVXAAM OPTION EXPIRING 28-NOV-2026 EX $0.01
IVXAAL OPTION EXPIRING 01-DEC-2026 EX $0.01
Announcement Type
New Announcement
Date of this announcement
15/10/2024
Reorganisation type
Security consolidation
Trading in the post consolidation or split +securities commences on a deferred settlement basis
20/11/2024
Record Date
21/11/2024
Issue Date
28/11/2024
Click here for the full ASX Release
This article includes content from Invion Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
IVX:AU
Sign up to get your FREE
Invion Limited Investor Kit
and hear about exciting investment opportunities.
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
10 April
Invion Limited
Revolutionizing Photodynamic Therapy (PDT) for cancer and infectious diseases
Revolutionizing Photodynamic Therapy (PDT) for cancer and infectious diseases Keep Reading...
02 December
Invion Secures Expanded Photosoft Global Exclusive License
Invion Limited (IVX:AU) has announced Invion Secures Expanded Photosoft Global Exclusive LicenseDownload the PDF here. Keep Reading...
30 October
Appendix 4C and Quarterly Activities Report - September 2025
Invion Limited (IVX:AU) has announced Appendix 4C and Quarterly Activities Report - September 2025Download the PDF here. Keep Reading...
20 October
Funded Collaboration Agreement with Protect Animal Health
Invion Limited (IVX:AU) has announced Funded Collaboration Agreement with Protect Animal HealthDownload the PDF here. Keep Reading...
09 October
Repayment of Lind Facility with Successful Capital Raise
Invion Limited (IVX:AU) has announced Repayment of Lind Facility with Successful Capital RaiseDownload the PDF here. Keep Reading...
07 October
Trading Halt
Invion Limited (IVX:AU) has announced Trading HaltDownload the PDF here. Keep Reading...
27 November
5 Biggest Pharmaceutical ETFs in 2025
The global pharmaceutical market is set to surpass a total value of US$1.75 trillion by the end of the decade, according to Evaluate Pharma.Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma... Keep Reading...
18 November
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901
Data demonstrate a favorable bioavailability profile of INM-901 oral formulationData will support design and planning of first in human clinical trialsPreparing for pre-IND meeting with the FDA InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company... Keep Reading...
04 November
4 Best-performing Canadian Pharma Stocks of 2025
From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are... Keep Reading...
30 October
New Deal Could Spark Invion’s Entry into Pet Cancer Market, CEO Says
Invion’s (ASX:IVX,OTC Pink:IVIXF) Photosoft cancer treatment technology has entered an important milestone, thanks to a new collaboration deal with Taiwanese firm Protect Animal Health, to undertake studies to treat cancer in pets.“The significance of this recent collaboration is (that) now... Keep Reading...
27 October
Appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth
Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, is delighted to announce the appointment of Paul Carter as Non-Executive Director, effective 27 October 2025.Paul Carter is a highly... Keep Reading...
Latest News
Sign up to get your FREE
Invion Limited Investor Kit
and hear about exciting investment opportunities.
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00